×
Enjoying ad-free content?
Since July 1, 2024, we have disabled all ads to improve your reading experience.
This commitment costs us $10,000 a month. Your support can help us fill the gap.
Support us
Our journalism is banned in Russia. We need your help to keep providing you with the truth.

Argentine Health Minister Visits Russia to Discuss Vaccine Supplies – TASS

Argentine health minister Carla Vizzotti (R) receiving the first batch of Sputnik V vaccines produced in Argentina. sputnikvaccine / twitter

Argentina’s health minister and presidential adviser are visiting Russia to discuss delays in the supplies of the Sputnik V coronavirus vaccine, the state-run TASS news agency reported Monday.

Argentina was among the first countries to use Sputnik V but hit “critical” second-dose shortages in late spring. 

Argentine presidential adviser Cecilia Nicolini said in a leaked July 7 email to Sputnik V makers that the contract was “at risk of being publicly canceled” due to a shortage of 18.5 million first and second doses.

According to TASS, Nicolini and health minister Carla Vizzotti have set off for Moscow to discuss the delays and seek information about boosters.

They will discuss with the Gamaleya Center a schedule of supplies and will share the results of joint study of [vaccine] combination,” the news agency quoted the Argentinian health ministry as saying.  

Nicolini and Vizzotti will also “receive information about progress in the study of vaccination among children and teenagers, which is being conducted in this country, and of the use of booster doses.

Vizzotti said earlier this month that Argentina will start offering second doses of the Moderna and AstraZeneca vaccines to those who have received the first dose of Sputnik V, according to Reuters. The decision to combine different vaccines followed preliminary results of a trial conducted by Argentine scientists showing it to be safe.

Like Russia, Argentina has been battling the more-contagious Delta variant of Covid-19.

The Russian Direct Investment Fund (RDIF), which markets Sputnik V worldwide, has promised to resolve the delays in August and double production in September through a partnership with the Serum Institute of India.

RDIF and Argentina’s Richment Laboratories have also promised to produce over 3 million second Sputnik V doses this month, according to Reuters.

Peer-reviewed research published earlier this year placed Sputnik V’s effectiveness at 91.6% despite earlier concerns of its approval and rollout ahead of large-scale trials.

A Message from The Moscow Times:

Dear readers,

We are facing unprecedented challenges. Russia's Prosecutor General's Office has designated The Moscow Times as an "undesirable" organization, criminalizing our work and putting our staff at risk of prosecution. This follows our earlier unjust labeling as a "foreign agent."

These actions are direct attempts to silence independent journalism in Russia. The authorities claim our work "discredits the decisions of the Russian leadership." We see things differently: we strive to provide accurate, unbiased reporting on Russia.

We, the journalists of The Moscow Times, refuse to be silenced. But to continue our work, we need your help.

Your support, no matter how small, makes a world of difference. If you can, please support us monthly starting from just $2. It's quick to set up, and every contribution makes a significant impact.

By supporting The Moscow Times, you're defending open, independent journalism in the face of repression. Thank you for standing with us.

Once
Monthly
Annual
Continue
paiment methods
Not ready to support today?
Remind me later.

Read more